Columbia Laboratories to Address Strategic Issues |
 |
 |
| Wednesday, 22 July 2009 06:47 |
|
Robert S. Mills, Columbia’s president and chief executive officer, stated, “We are pleased that Frank has agreed to devote his time to this effort. Frank’s long time experience in business development and commercial operations in the pharmaceutical industry will serve us well. We look forward to his leadership in this area.” Mr. Condella was chief executive officer of Skyepharma plc from March 2006 to September 2008, president of European operations at IVAX Corporation from 2002 to February 2006, and president and chief executive officer of Faulding Pharmaceutical Co., from 2000 to 2001. Previously he was vice president of Specialty Care Products at Hoffman-La Roche and vice president and general manager of the Lederle unit of American Home Products. About Columbia Laboratories Columbia Laboratories, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the women’s healthcare and endocrinology markets that use its novel bioadhesive drug delivery technology. Columbia markets CRINONE® 8% (progesterone gel) in the United States for progesterone supplementation as part of an ART treatment for infertile women with progesterone deficiency. The Company also markets STRIANT® (testosterone buccal system) for the treatment of hypogonadism in men. The Company’s partners market CRINONE® 8%, STRIANT®, and three other products to additional U.S. and foreign markets. The Company is conducting, in collaboration with the NIH, the PREGNANT (PROCHIEVE® Extending GestatioN A New Therapy) Study of PROCHIEVE® 8% to reduce the risk of preterm birth in women with a short cervix at mid-pregnancy. For more information, please visit www.columbialabs.com. BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
LIVINGSTON, N.J.--Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced that Frank C. Condella, Jr., the most recent addition to the Company’s Board of Directors and a seasoned pharmaceutical executive, will be working closely with management and the Board over the next three months to advise on strategic issues. Mr. Condella will serve a key role in evaluating strategic alliances that would complement Columbia’s current efforts with marketed products and maximize the potential for value creation from the Company’s late-stage R&D pipeline.
Free Phone Trade Alerts
